Polypeptides and uses thereof for reducing CD95-mediated cell motility
The present invention relates to polypeptides and uses thereof for reducing CD95-meditated cell motility. In particular, the present invention relates to a polypeptide having an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino-acid residue at position 175 to the amino-acid residue at position 191 in SEQ ID NO:1.
1. A nucleic acid sequence encoding for a fusion protein comprising a polypeptide having an amino acid sequence having at least 96, 97, 98, 99, or 100% identity with an amino acid sequence ranging from an amino acid residue at position 175 to an amino acid residue at position 209 or 210 as set forth in SEQ ID NO: 1, wherein said polypeptide is fused to a heterologous cell-penetrating polypeptide.
2. A vector and an expression cassette in which the nucleic acid sequence of claim 1 is associated with suitable elements for controlling transcription and, optionally translation.
3. A host cell comprising the vector of claim 2 .
4. The host cell of claim 3 which is a prokaryotic or eukaryotic host cell genetically transformed with the vector.
5. A host cell comprising the nucleic acid sequence of claim 1 .
6. The host cell of claim 5 which is a prokaryotic or eukaryotic host cell genetically transformed with the nucleic acid sequence.
7. A method of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a fusion protein comprising a polypeptide having an amino acid sequence having at least 96, 97, 98, 99, or 100% identity with an amino acid sequence ranging from an amino acid residue at position 175 to an amino acid residue at position 209 or 210 as set forth in SEQ ID NO: 1, wherein said polypeptide is fused to a heterologous cell-penetrating polypeptide.
8. The method of claim 7 wherein the subject suffers from a triple negative breast cancer.
9. A method of treating an auto-immune disease or an inflammatory condition in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a fusion protein comprising a polypeptide having an amino acid sequence having at least 96, 97, 98, 99, or 100% identity with an amino acid sequence ranging from an amino acid residue at position 175 to an amino acid residue at position 209 or 210 as set forth in SEQ ID NO: 1, wherein said polypeptide is fused to a heterologous cell-penetrating polypeptide.
10. The method of claim 9 wherein the subject suffers from systemic lupus erythematosus.
11. A method of treating a Th17 mediated disease condition in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a fusion protein comprising a polypeptide having an amino acid sequence having at least 96, 97, 98, 99, or 100% identity with an amino acid sequence ranging from an amino acid residue at position 175 to an amino acid residue at position 209 or 210 as set forth in SEQ ID NO: 1, wherein said polypeptide is fused to a heterologous cell-penetrating polypeptide.
12. A pharmaceutical composition comprising a fusion protein comprising a polypeptide having an amino acid sequence having at least 96, 97, 98, 99, or 100% identity with an amino acid sequence ranging from an amino acid residue at position 175 to an amino acid residue at position 209 or 210 as set forth in SEQ ID NO: 1, wherein said polypeptide is fused to a heterologous cell-penetrating polypeptide.
13. A method for screening a drug for reducing CD95-mediated cell motility comprising the steps consisting of a) determining the ability of a candidate compound to inhibit the interaction between CD95 and a fusion protein comprising a polypeptide having an amino acid sequence having at least 96, 97, 98, 99, or 100% identity with an amino acid sequence ranging from an amino acid residue at position 175 to an amino acid residue at position 209 or 210 as set forth in SEQ ID NO: 1, wherein said polypeptide is fused to a heterologous cell-penetrating polypeptide and b) positively selecting the candidate compound that inhibits said interaction.